Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
New AAV 3.0 program to create next-generation viral vectors for better treatment of inherited diseases

New AAV 3.0 program to create next-generation viral vectors for better treatment of inherited diseases

Study highlights role of CMV in patients with leukemia after bone marrow transplantation

Study highlights role of CMV in patients with leukemia after bone marrow transplantation

LIF-treated muscle stem cells show promise in treatment of muscular dystrophy

LIF-treated muscle stem cells show promise in treatment of muscular dystrophy

Blocking c-Abl enzyme prevents Parkinson’s disease progression in mice

Blocking c-Abl enzyme prevents Parkinson’s disease progression in mice

Scientists detect gene networks likely to be shared by all CLL patients

Scientists detect gene networks likely to be shared by all CLL patients

Vice President Biden to host Cancer Moonshot Summit in Washington, D.C.

Vice President Biden to host Cancer Moonshot Summit in Washington, D.C.

Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists discover how faulty genetic instructions contribute to development of AML

Scientists discover how faulty genetic instructions contribute to development of AML

Scientists streamline total synthesis of uncialamycin drug

Scientists streamline total synthesis of uncialamycin drug

New CAR-based therapy using combined cancer target could be effective for solid tumors

New CAR-based therapy using combined cancer target could be effective for solid tumors

Telephone counseling can help make cancer genetic services more accessible to rural women

Telephone counseling can help make cancer genetic services more accessible to rural women

Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Elevated levels of CXCL10 protein could help diagnose cGvHD in blood, bone marrow transplant patients

Elevated levels of CXCL10 protein could help diagnose cGvHD in blood, bone marrow transplant patients

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Already-approved drugs can fight apoptosis evasion in cancer

Already-approved drugs can fight apoptosis evasion in cancer

Interdisciplinary approach to improve cancer treatments

Interdisciplinary approach to improve cancer treatments

NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.